Clinical Efficacy and Cost-Effectiveness of Lanthanum Carbonate as Second-Line Therapy in Hemodialysis Patients in Japan

Abstract

SummaryBackground and objectives Lanthanum carbonate (LC) is a nonaluminum, noncalcium phosphate binder that is effective for hyperphosphatemia in dialysis patients. However, its efficacy and cost-effectiveness as second-line therapy have not been fully examined.

Chronic Kidney Disease-Mineral and Bone Disorder in Asia

“…Policies for publishing and sharing of data regarding Asian CKD patients is most urgently required [48] , which should include data on pre-dialysis CKD patients and kidney transplant recipients [49] . Such data should also include costeffectiveness analyses [50,51] that take the local medical costs and system into consideration.…”

Cost-Minimization Analysis of Lanthanum Carbonate Versus Sevelamer Hydrochloride in US Patients With End-stage Renal Disease

“…In addition, several other economic evaluations have demonstrated the cost-effectiveness of lanthanum carbonate as second-line treatment for hyperphosphatemia from UK, US, Canadian, Japanese, and Australian payer perspectives. 22,24,[33][34][35] The primary limitations of the present evaluation are those inherent to post hoc analyses of clinical data. 36 A limitation common to health economic analyses is that although ESRD and hyperphosphatemia are chronic conditions, our analyses of the comparative cost-effectiveness of sevelamer hydrochloride and lanthanum carbonate were limited to a relatively short duration (16 weeks).…”

Real-World Dose-Relativity, Tablet Burden, and Cost Comparison of Conversion Between Sevelamer Hydrochloride/Carbonate and Lanthanum Carbonate Monotherapies

“…21,22 The results of the cost analyses presented here are consistent with previous economic evaluations demonstrating the cost-effectiveness of lanthanum carbonate as second-line treatment for hyperphosphatemia from Australian, Canadian, Japanese, UK, and US payer perspectives. [30][31][32][33][34] Several limitations of the study should be noted. These analyses were limited to patients enrolled in the LDO's pharmacy management program.…”